Vitamin C as a Cardioprotective Agent Against Doxorubicin‐Induced Cardiotoxicity

Vitamin C as a Cardioprotective Agent Against Doxorubicin‐Induced Cardiotoxicity

Doxorubicin is used and highly effective chemotherapeutic agent; however, its clinical utility remains limited by dose‐dependent cardiotoxicity, presenting a significant challenge in cancer management. Growing preclinical research and clinical evidence suggest that the antioxidant vitamin C (ascorbi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hamdi Nsairat, Zainab Lafi, Bassam M. Abualsoud, Belal O. Al‐Najjar, Ali Al‐Samydai, Ghaleb Ali Oriquat, Walhan Alshaer, Abed Alqader Ibrahim, Anthony L. Dellinger
Format:	Article
Language:	English
Published:	Wiley 2025-08-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	cardioprotection doxorubicin‐induced cardiotoxicity oxidative stress reactive oxygen species vitamin C
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.125.042534
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review
by: Shang W, et al.
Published: (2025-07-01)

Combined effects of metformin and coenzyme Q10 on doxorubicin-induced cardiotoxicity in male wistar rats
by: Faraz Mahdizadeh, et al.
Published: (2025-07-01)

CARDIOPROTECTIVE EFFECT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONIST IN DOXORUBICIN MYOCARD TOXICITY
by: M. I. Popovich, et al.
Published: (2018-02-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al.

Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin
by: Fouad Zeidan Hamzah, et al.
Published: (2025-07-01)

Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity
by: Jingjing Ding, et al.
Published: (2025-04-01)

Promising Mesenchymal Stem Cell Intervention for Relieving Cardiac Recovery against Cardiotoxic Injury Modeling with Doxorubicin: A Novel Therapeutic Approach
by: Ozgermen Deva Basak Boztok, et al.
Published: (2025-06-01)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01)

Photobiomodulation Therapy Reduces Oxidative Stress and Inflammation to Alleviate the Cardiotoxic Effects of Doxorubicin in Human Stem Cell-Derived Ventricular Cardiomyocytes
by: Guilherme Rabelo Nasuk, et al.
Published: (2025-07-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Clinicopathological Studies on the Impact of Grape Seed Extract and L-Carnitine as Cardioprotective Agents Against Doxorubicin-Induced Toxicity in Rats
by: Tahany Saleh Aldayel, et al.
Published: (2024-12-01)

Research on Doxorubicin-Induced Cardiotoxicity Mechanism and Its Forensic Application
by: ZHANG Shuai, et al.
Published: (2025-04-01)

5-Oxoproline prevents doxorubicin-induced cardiotoxicity and tumor growth
by: Xinning Guo, et al.
Published: (2025-09-01)

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01)

Bioinformatics analysis of ferroptosis-related biomarkers and potential drug predictions in doxorubicin-induced cardiotoxicity
by: Jian Yu, et al.
Published: (2025-04-01)

Micellar Nanoformulation of Berberine to Mitigate Doxorubicin-induced Cardiotoxicity: A Cell-line Study
by: Noora Alyasari, et al.
Published: (2023-12-01)

Non-Coding RNAs in the Regulation of Doxorubicin-Induced Cardiotoxicity
by: Mengyao Sun, et al.
Published: (2025-05-01)

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future
by: A. M. Chaulin, et al.
Published: (2022-03-01)

Tetrahedral Framework Nucleic Acids Inhibit Oxidative Stress and Cardiomyocyte Apoptosis in Doxorubicin-Induced Cardiotoxicity
by: Pan H, et al.
Published: (2025-07-01)

Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis
by: Christopher W. Hoeger, et al.
Published: (2025-07-01)

Longitudinal Assessment of QT Apex in Tumor‐Bearing Dogs Receiving Doxorubicin Monotherapy
by: Keita Kitagawa, et al.
Published: (2025-07-01)

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer
by: Atefeh Ghahremanloo, et al.
Published: (2025-03-01)

Role of mitochondrial fusion in doxorubicin-induced cardiotoxicity
by: WANG Yuqi, WANG Xinyu, LUO Haowen, LU Zhaoxin, ZHAO Yiwei, CHANG Pan
Published: (2025-01-01)

Apelinergic System Affects Electrocardiographic Abnormalities Induced by Doxorubicin
by: Kasper Buczma, et al.
Published: (2025-01-01)

Caffeic Acid Phenethyl Ester Protects Against Doxorubicin-Induced Cardiotoxicity via Inhibiting the ROS-MLKL-Mediated Cross-Talk Between Oxidative Stress and Necroptosis
by: Chenying Jiang, et al.
Published: (2025-05-01)

Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies
by: Megha Nair, et al.
Published: (2025-04-01)

Neuraminidase 1 Exacerbated Glycolytic Dysregulation and Cardiotoxicity by Destabilizing SIRT1 through Interactions with NRF2 and HIF1α
by: Ting Gao, et al.
Published: (2025-07-01)

PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer
by: Bingting Li, et al.
Published: (2023-12-01)

Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update
by: Vasvi Bhutani, et al.
Published: (2025-05-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Cardiotoxicity of Anticancer Drugs
by: I. Maiborodin, et al.
Published: (2025-02-01)

Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity
by: Emilia ANCA, et al.
Published: (2024-12-01)

Cardioprotective effects of dapagliflozin against the acute cardiotoxic effects of 5-fluorouracil
by: Mehmet Hakan Uzun, et al.
Published: (2025-07-01)

Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy
by: Yu. A. Vasyuk, et al.
Published: (2023-01-01)

Cardioprotective, anti-inflammatory, and antioxidative outcome of costus against bleomycin-induced cardiotoxicity in rat model
by: Barakat M. Alrashdi, et al.
Published: (2025-03-01)

Curcumin exerts protective effects against doxorubicin-induced cardiotoxicity
by: O. О. Klymenko, et al.
Published: (2025-02-01)

Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
by: Hui-Ming Chang, et al.
Published: (2025-05-01)

The role of HDAC2 inhibition in cardioprotection against doxorubicin-induced myocardial injury
by: Jinsha Liu, et al.
Published: (2025-02-01)

Investigation of cardiotoxic effects of marbofloxacin
by: Devran Coşkun, et al.